Dissociative Disorder
Conditions
Brief summary
Dissociative symptoms and disorders are particularly prevalent in the general population and among people suffering from psychiatric disorders. To date, no treatment has proven effective for this type of problem. Exploratory studies (without control group) have been carried out. Among these studies, dissociation-focused cognitive behavioral therapy (DF-CBT) seems promising. DF-CBT is based on a solid empirical model that has received numerous scientific evidence.
Interventions
OTHERCBT-CD psychotherapy
9 weekly sessions of CBT-CD psychotherapy
Sponsors
University Hospital, Tours
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ≥ 18 years * Membership of a social security scheme * Participant's express consent * Have at least one diagnosis of dissociative disorder among the following: depersonalization/derealization disorder, dissociative identity disorder, unspecified dissociative disorder. * Be able to carry out psychotherapy sessions. * If taking psychiatric medication, treatment must have been stable for at least 30 days.
Exclusion criteria
* Present one of the following current diagnoses: substance use disorder (excluding tobacco), neurodevelopmental disorder, anorexia nervosa, severe depressive disorder, schizophrenia spectrum disorder, bipolar disorder, personality disorder other than borderline personality disorder. * Present cognitive deficits. * Be engaged in psychotherapeutic work. * Be undergoing benzodiazepine treatment. * Pregnant women and breastfeeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Difference in Dissociative Experience Scale (DES) | Between randomization and 3 months after | Difference in Dissociative Experience Scale (DES) between randomization and 3 months after. The DES assesses dissociation through 28 items. The total score ranges between 0 and 100, where high scores indicate high levels of dissociation. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hetero-administered visual analogue scale | At randomization, 3 months and 6 months after | Visual analogue scales in which the practitioner rates the intensity of the patient's dissociative symptoms on the basis of his/her clinical assessment. |
| Dissociation Questionnaire (DIS-Q) | At randomisation, 3 months and 6 months after | The Dissociation Questionnaire is a 63-item questionnaire measuring dissociative-trait manifestations. Participants respond to each item using a 5-point Likert scale. Four sub-scores (loss of control, absorption, amnesia and identity confusion) are calculated. |
| Hospital Anxiety Depression Scale (HADS) | Randomization, 3 months and 6 months after | Hospital Anxiety Depression Scale (HADS) is a 14-item self-report questionnaire. Two sub-scores (anxiety and depression) are calculating. Both scores range between 0 and 21 with 0 corresponding to the ideal score (no anxiety or depression symptoms). |
| Post traumatic stress disorder checklist scale (PCL-5) | Randomization, 3 months and 6 months after | The post traumatic stress disorder checklist scale (PLC-5) is 20-item scale to assess post-traumatic stress symptoms. Participants respond to each item using a 5-point Likert scale. The score ranges between 0 and 80, with 0 reflecting no post traumatic stress disorder. |
| Satisfaction With Life Scale (SWLS) | Randomization, 3 months and 6 months after | The Satisfaction With Life Scale (SWLS) is a 5-item questionnaire assessing quality of life. Participants respond to each item using a 7-point Likert scale. The score range bewteen 0 and 35 with 35 reflects an extreme satisfaction with life. |
| Dissociative Experiences Scale (DES) | At 6 months after randomization | The DES assesses dissociation through 28 items. The total score ranges between 0 and 100, where high scores indicate high levels of dissociation. |
Countries
France
Contacts
CONTACTAlexis VANCAPPEL, PhD
STUDY_CHAIRAlexis VANCAPPEL, PhD
Unité de Neuromodulation / CHU de Tours
PRINCIPAL_INVESTIGATORWissam EL HAGE, MD-PhD
Unité de Neuromodulation / CHU de Tours
Outcome results
None listed